Skip to main content
. Author manuscript; available in PMC: 2012 Oct 20.
Published in final edited form as: Cell Host Microbe. 2011 Oct 20;10(4):379–389. doi: 10.1016/j.chom.2011.08.015

Table 2.

(see also figure S1)Inhibitory activity of tenofovir and adefovir against HSV-2 in primary monocyte/macrophage cultures using the CPE reduction assay and the PFU reduction assay*

Treatment Virus
production
(TCID50/ml)		 Inhibition
of virus
production
(% of control)
CPE reduction
assay		 Virus
production
(PFU/ml)		 Inhibition
of virus
production
(% of control)
PFU reduction
assay		 Cytopathicity
(CPE)
(%)
None 3.7 ×105 9×104 95
Tenofovir (μg/ml)
500 No virus 100 No virus 100 None
100 No virus 100 No virus 100 None
20 1.3×104 96 2.2×103 98 5
5 7.2× 104 80 1.9×104 79 60
1 2.4×105 34 6.6×104 27 70
0.2 3×105 19 7.3×104 19 80
0.04 3.2×105 13 8.5×104 6 85
Adefovir (μg/ml)
500 No virus 100 No virus 100 None
100 No virus 100 No virus 100 None
20 No virus 100 No virus 100 None
5 No virus 100 No virus 100 None
1 8×102 99 2.5×102 99 None
0.2 6×104 84 9.9×103 89 5
0.04 1×105 73 1.8×104 80 40
*

Virus production was evaluated on day 6 post infection. HSV-2 was quantified in the supernatants of drugtreated virus-infected cell cultures by titration in Vero cell cultures using the CPE reduction assay (calculation of TCID50/ml) and the PFU reduction assay (calculation of PFU/ml).